Insider Transactions in Q4 2020 at Arena Pharmaceuticals Inc (ARNA)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2020
|
Jayson Donald Alexander Dallas Director |
BUY
Open market or private purchase
|
Direct |
5
+0.08%
|
$345
$69.31 P/Share
|
|
Dec 08
2020
|
Amit Munshi President and CEO |
SELL
Open market or private sale
|
Direct |
6,517
-45.68%
|
$456,190
$70.0 P/Share
|
|
Dec 08
2020
|
Jayson Donald Alexander Dallas Director |
BUY
Open market or private purchase
|
Direct |
5
+0.08%
|
$330
$66.25 P/Share
|
|
Dec 01
2020
|
Robert Lisicki EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,872
-64.12%
|
$251,680
$65.88 P/Share
|
|
Nov 25
2020
|
Amit Munshi President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,183
-26.65%
|
$336,895
$65.5 P/Share
|
|
Nov 25
2020
|
Amit Munshi President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,700
+37.56%
|
-
|
|
Nov 25
2020
|
Vincent Aurentz Executive VP and CBO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+50.0%
|
-
|
|
Nov 25
2020
|
Christopher Cabell EVP, Head of R&D, and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-43.96%
|
$71,435
$65.5 P/Share
|
|
Nov 25
2020
|
Christopher Cabell EVP, Head of R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
-
|
|
Nov 25
2020
|
Robert Lisicki EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,428
-38.54%
|
$157,820
$65.5 P/Share
|
|
Nov 25
2020
|
Robert Lisicki EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,300
+50.0%
|
-
|